Ipamorelin/Tesamorelin

Ipamorelin/Tesamorelin is a research peptide blend containing a GHRP (ipamorelin) and a GHRH analog (tesamorelin). Tesamorelin is FDA-approved for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Ipamorelin has no approved human use. In non-medical contexts, this combination is commonly referenced for GH stimulation, though such use falls outside approved indications.

Because the blend contains equal amounts of each peptide, dosing requires accounting for the fixed 1:1 ratio. Clinical tesamorelin dosing is 1.28–2 mg once daily. Community ipamorelin protocols reference 200–300 mcg per administration. A blend dose of 200–300 mcg total would deliver 100–150 mcg of each peptide. Common reference ranges for this specific combination are not well characterized.

Neither component suppresses endogenous testosterone production, as both act on the GH axis rather than the hypothalamic-pituitary-gonadal axis. Post-cycle therapy is therefore not applicable in the context of testosterone recovery. A break between cycles is commonly referenced to allow GH receptor resensitization.

Ipamorelin stimulates GH release by activating the ghrelin receptor (GHS-R1a) with minimal effects on cortisol or prolactin. Tesamorelin is a GHRH analog that binds GHRH receptors on the pituitary to stimulate GH synthesis and pulsatile release. Together they activate complementary GH-release pathways.

Tesamorelin has a short half-life of 26–38 minutes, while ipamorelin has a half-life of approximately 2 hours. Effects on GH and IGF-1 levels occur after each administration. In clinical studies, tesamorelin at 2 mg daily increased mean overnight GH secretion by approximately 70% and more than doubled IGF-1 after 2 weeks.

There is no single GH protocol that is universally best. This blend combines a selective GHRP with an FDA-approved GHRH analog. Ipamorelin alone is more commonly used in community protocols, and CJC 1295 No DAC/Ipamorelin is a more frequently referenced GHRP+GHRH combination. The appropriate choice depends on individual goals and risk tolerance.

Ipamorelin alone provides selective GHRP-class GH stimulation with minimal side effects. The addition of tesamorelin introduces GHRH-receptor activation for a complementary mechanism. Tesamorelin also carries the side effect profile and monitoring requirements of an FDA-approved GHRH analog.

CJC 1295 No DAC/Ipamorelin pairs ipamorelin with a different GHRH analog (Mod GRF 1-29). Both combinations use the same GHRP component but different GHRH analogs. Tesamorelin is a stabilized GHRH analog with FDA approval for a specific indication, while Mod GRF 1-29 is not FDA-approved.

200 mcg total would deliver 100 mcg of each peptide. For reference, clinical tesamorelin dosing is 1.28–2 mg (1,280–2,000 mcg) daily. Community ipamorelin protocols reference 200–300 mcg per administration. The 10 mg vial contains 5,000 mcg of each peptide, providing 16–50 doses depending on protocol.

Ipamorelin/Tesamorelin is labeled at 10 mg total peptide content per vial, consisting of 5 mg Ipamorelin and 5 mg Tesamorelin. It is supplied as a lyophilized powder in a 2 mL vial.

Yes. A published laboratory report dated November 10, 2025 measured Ipamorelin/Tesamorelin at 5.47 mg Ipamorelin (109.4% of label claim) and 5.33 mg Tesamorelin (106.6% of label claim). The batch number for this report is #HDIT10.

The complete report can be viewed in the Lab Reports tab. Laboratory results apply to the tested sample represented by the individual report and should not be interpreted as a measurement of every vial.

Lyophilized Ipamorelin/Tesamorelin is typically reconstituted with a suitable solvent such as Bacteriostatic Water or sterile water. The volume of solvent added determines the concentration of the resulting solution. Proper sterile technique should be used during reconstitution.